Paper Details

  1. Home
  2. Paper Details

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.

Author: DengLijuan, DingNing, HeYizi, LiJiao, LiuWeiping, PingLingyan, SongYuqin, WangXiaogan, XieYan, YingZhitao, ZhangChen, ZhuJun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigates the synergistic anti-tumor effects of combining enzastaurin, a protein kinase C-β (PKCβ) inhibitor, with ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, in diffuse large B cell lymphoma (DLBCL), a common form of lymphoma.
Paper Details　
Original Abstract of the Article :
Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of patients not being cured. BCR-associated kinases (SYK, BTK, and PI3K) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379963/

データ提供：米国国立医学図書館（NLM）

A Powerful Combination: Unlocking the Potential of Enzastaurin and Ibrutinib for Diffuse Large B Cell Lymphoma

Diffuse large B cell lymphoma (DLBCL) is a challenging form of cancer. This study delves into the potential of combining two targeted therapies, enzastaurin and ibrutinib, for treating this aggressive lymphoma. The researchers explore the synergistic effects of these drugs, suggesting that this combination could be a powerful weapon in the fight against DLBCL.

A New Oasis in the Desert of Lymphoma Treatment

The study highlights the potential of combining enzastaurin and ibrutinib, two targeted therapies that inhibit specific kinases involved in B cell lymphoma development. The researchers explore the synergistic effects of these drugs, suggesting that this combination could be a more effective treatment option for DLBCL. This research offers hope for patients seeking new and effective therapies for this challenging disease.

A Journey Through the Labyrinth of Cancer Treatment

The study's findings suggest that combining enzastaurin and ibrutinib could be a promising approach to treating DLBCL. The researchers highlight the synergistic effects of these drugs, suggesting that this combination could lead to more effective and durable responses. The study underscores the importance of exploring new and innovative treatment strategies for cancer, offering hope for patients seeking effective therapies and improved outcomes.

Dr. Camel's Conclusion

This study offers a glimpse into the future of cancer treatment, where targeted therapies and synergistic combinations could offer a more effective and personalized approach to managing complex diseases. The research provides hope for patients seeking new and effective treatment options for DLBCL, offering a potential path towards improved outcomes and a brighter future for those affected by this challenging disease.

Date :
  1. Date Completed 2019-05-29
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30777096

DOI: Digital Object Identifier

PMC6379963

Related Literature

Article Analysis
・Effects of ibrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.